Metabolic Pathway-Targeted Therapy in ALS

Metabolic Pathway-Targeted Therapy in ALS

Experiment Overview

Rank: 109 | Score: 72/100 | Category: Translational | Disease: Amyotrophic Lateral Sclerosis

Hypothesis

Targeting systemic metabolic dysfunction — including hypermetabolism, lipid dysregulation, and glucose intolerance — will slow ALS progression and improve survival.

Knowledge Gap Addressed

Addresses the "Systemic Metabolic Dysfunction in ALS Progression" gap — specifically, whether metabolic interventions can modify disease course.

Scientific Rationale

ALS involves significant systemic metabolic dysfunction:

• Hypermetabolism: ~60% of ALS patients have elevated resting energy expenditure
• Lipid alterations: Reduced HDL, elevated triglycerides correlate with faster progression
• Glucose intolerance: Insulin resistance observed in subset
• Muscle hypometabolism: Early metabolic defects in muscle

Metabolic dysfunction may be:

• A driver of progression (via energy deficit)
• A consequence (via denervation)
• Both (feedback loop)

Targeting metabolism could preserve muscle function, support neural energetics, and slow progression.

Why This Matters

• ALS median survival is 2-4 years
• Riluzole and edaravone provide limited benefit
• Metabolic interventions are low-risk
• May preserve function even if not disease-modifying

Validation Protocol

Study Design

Type: Multi-arm randomized controlled trial

...

Metabolic Pathway-Targeted Therapy in ALS

Experiment Overview

Rank: 109 | Score: 72/100 | Category: Translational | Disease: Amyotrophic Lateral Sclerosis

Hypothesis

Targeting systemic metabolic dysfunction — including hypermetabolism, lipid dysregulation, and glucose intolerance — will slow ALS progression and improve survival.

Knowledge Gap Addressed

Addresses the "Systemic Metabolic Dysfunction in ALS Progression" gap — specifically, whether metabolic interventions can modify disease course.

Scientific Rationale

ALS involves significant systemic metabolic dysfunction:

• Hypermetabolism: ~60% of ALS patients have elevated resting energy expenditure
• Lipid alterations: Reduced HDL, elevated triglycerides correlate with faster progression
• Glucose intolerance: Insulin resistance observed in subset
• Muscle hypometabolism: Early metabolic defects in muscle

Metabolic dysfunction may be:

• A driver of progression (via energy deficit)
• A consequence (via denervation)
• Both (feedback loop)

Targeting metabolism could preserve muscle function, support neural energetics, and slow progression.

Why This Matters

• ALS median survival is 2-4 years
• Riluzole and edaravone provide limited benefit
• Metabolic interventions are low-risk
• May preserve function even if not disease-modifying

Validation Protocol

Study Design

Type: Multi-arm randomized controlled trial

Population:

• Definite or probable ALS (Awaji or revised El Escorial)
• Disease duration <24 months
• Age 18-80
• Not on metabolic drugs (metformin, statins)

Metabolic Targeting Arms

Arm A (Caloric Restriction Mimetic):

• Agent: Metformin 500mg BID
• Rationale: Improves insulin sensitivity, activates AMPK, extends lifespan

Arm B (Lipid-Targeted):

• Agent: Omega-3 fatty acids (EPA+DHA 2g/day)
• Statin: Atorvastatin 20mg (if elevated LDL)
• Rationale: Lipid alterations drive progression

Arm C (Combination Metabolic):

• Metformin + Omega-3 + CoQ10 300mg
• Rationale: Multi-target metabolic support

Arm D (Control):

• Standard of care

Metabolic Monitoring

| Biomarker | Timing | Purpose |
|----------|--------|---------|
| Fasting glucose/insulin | Baseline, M3, M6, M12 | Insulin sensitivity |
| HOMA-IR | Baseline, M6, M12 | Metabolic status |
| Lipid panel | Baseline, M3, M6, M12 | Lipid status |
| Resting energy expenditure (REE) | Baseline, M6 | Metabolic rate |
| Body composition (DEXA) | Baseline, M6, M12 | Muscle/fat |
| Creatinine | Baseline, M6, M12 | Muscle mass |

Sample Size

n=320 (80 per arm)

• Power: 80% to detect 25% slower ALSFRS-R decline
• Alpha: 0.05
• Accounting for 15% attrition

Duration

24 months

• Interim analysis at 12 months
• Primary endpoint at 24 months

Model Systems

Preclinical

• SOD1G93A mouse metabolic profiling
• Zebrafish muscle metabolism models
• iPSC motor neurons with metabolic defects

In Vitro

• Muscle biopsy metabolic assays
• Fibroblast bioenergetics (Seahorse)
• Lipidomics

Expected Outcomes

Primary Endpoint

• ALSFRS-R slope at 24 months
• Comparing metabolic arms to control

Secondary Endpoints

Survival: Time to death/tracheostomy

FVC decline: Respiratory function

Body weight: Nutritional status

Quality of life: ALSAQ-40

Hypothesized Results

• Combination metabolic therapy slows ALSFRS-R by 2-4 points
• May improve survival by 3-6 months
• Best response in hypermetabolic subgroup

Feasibility Assessment

Technical Feasibility: 8/10

• All agents generic and available
• Metabolic monitoring standard
• Low-risk interventions

Cost Estimate

| Component | Cost |
|-----------|------|
| Study drug | $800/patient |
| Metabolic testing | $1,400/patient |
| Clinical visits | $2,400/patient |
| DEXA/imaging | $600/patient |
| Total | $5,200/patient |
| Project total | $1.7M |

Timeline

• Preparation: 6 months
• Enrollment: 12 months
• Follow-up: 12 months
• Analysis: 3 months
• Total: 33 months

Risk Mitigation

Risks and Mitigations

| Risk | Probability | Impact | Mitigation |
|------|-------------|--------|------------|
| Gastrointestinal effects | Medium | Low | Dose titration |
| Drug interactions | Low | Medium | Review concomitant meds |
| Nutritional decline | Medium | Medium | Dietician support |

Stopping Rules

• >20% withdrawal due to GI: Modify dose
• Clear efficacy: Early termination
• Safety signal: Review by DSMB

Cross-Disease Value

Metabolic targeting in ALS informs:

• Metabolic approaches in AD
• Energy dysfunction in PD
• General metabolic therapy frameworks

References

[Pagano et al., Metabolic dysfunction in ALS (2018)](https://pubmed.ncbi.nlm.nih.gov/30549673/)

[Dupuis et al., Energy metabolism in neurodegenerative diseases (2021)](https://pubmed.ncbi.nlm.nih.gov/33938204/)

[Werth et al., Lipid metabolism alterations in ALS (2024)](https://pubmed.ncbi.nlm.nih.gov/38371560/)

[Kim et al., Glucose intolerance in ALS (2024)](https://pubmed.ncbi.nlm.nih.gov/38492837/)

[Ferrari et al., ALS and metabolic disorders (2019)](https://pubmed.ncbi.nlm.nih.gov/31177245/)